About Hypermarker
Hypermarker is a research project aimed at personalised pharmacometabolomic optimisation of treatment for hypertension. Our team of experts is dedicated to finding innovative solutions in the field of hypertension treatment. We strive to combine the latest scientific research with a patient-centric approach to provide the best possible outcomes for our patients.
The research concept of Hypermarker can be outlined in 4 phases. Each of them is planned to last for about a year.
First phase includes the collection of clinical data and blood samples which will be analysed for their pharmacometabolomic profile in Leiden.
In the second phase, a predictive model will be generated at Birmingham University based on the results of this analysis.
This model will then be validated in the third phase in a small clinical trial to test if the model can be used in clinical practice.
In the fourth and last phase, a clinical decision tool and companion diagnostics tool will be designed. These could be later commercialised.
Expected Outcomes at the Project Conclusion
Enhanced Treatment Personalisation
Hypermarker is developing a clinical decision support tool that integrates pharmacometabolomics, aimed at tailoring hypertension treatment to individual patients' metabolic profiles. This innovative approach is expected to improve treatment efficiency, reduce adverse effects, and decrease the reliance on polypharmacy, thereby easing the burden on healthcare providers and payers.
Companion Diagnostic Development
The project is focused on creating and clinically validating a pharmacometabolomic-based companion diagnostic that facilitates smarter prescription practices for antihypertensive drugs. This effort includes developing strategies for regulatory approval and clinical adoption, ensuring safe and optimised treatment protocols.
Market Transition for Diagnostic Tools
Hypermarker is setting a benchmark in the diagnostics industry by demonstrating the utility of pharmacometabolomics in hypertension management. This 'proof of concept' paves the way for broader application in other therapeutic areas, enhancing treatment efficacy and leading the shift towards market approval of new diagnostic tools.
Long-Term Impact Beyond the Hypermarker Completion
Enhanced Healthcare
Hypermarker leverages pharmacometabolomics to tailor hypertension treatments to individual needs, promoting safer and more effective care. This personalised approach not only improves patient outcomes but also optimises resource use, making healthcare more sustainable.
Economic and Health Efficiency
By developing potential companion diagnostic tests and optimising treatment protocols, Hypermarker aims to reduce adverse effects and healthcare costs, contributing to more affordable care and alleviating the societal burden of diseases like hypertension.
Ethical and Privacy-Focused Innovation
The Hypermarker project employs a 'privacy by design' strategy to integrate FAIR Digital Twin principles, ensuring that patient data is handled with utmost respect for privacy and ethical standards, enhancing public trust in health technologies.
Collaborative Health Innovation
Hypermarker engages patients and stakeholders in a co-creation process upholding values like non-discrimination and open science. This approach boosts the relevance and acceptance of health innovations, ensuring efficient service to the public good.